Multiple Myeloma
Conditions
Interventions
Bortezomib (1 mg/m2) was administered intravenously on days -6, -3, 1, and 4. Dexamethazone (20 mg) was administered orally on days -6,-5, -3, -2, 1, 2, 4, and 5. Melphalan was administered intravenou
Sponsors
National Hospital Organization Disaster Medical Center of Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: According to the International Myeloma Working Group (IMWG) criteria20, patients younger than 65 years with symptomatic MM were eligible for this trial.
Exclusion criteria
Exclusion criteria: The exclusion criteria were a serum creatinine level2.05 mg/dL at time of high-dose therapy (HDT), liver dysfunction (e.g., a serum total bilirubin level2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To investigate the safety of BD-HDM before ASCTin younger Japanese patients with MM | — |
Countries
Japan
Contacts
Public ContactYasuharu Sasaki
JCRAC Data Center
Outcome results
None listed